Tirzepatide Peptide Research Guide
For laboratory and research use only. Not for human or veterinary use. This page summarizes published scientific literature for educational purposes only.
Tirzepatide is the most-studied dual-agonist molecule in the incretin field and a key reference compound in metabolic research. This guide covers how the tirzepatide peptide works, what the published clinical literature reports, its half-life, and how laboratories reconstitute it. It is part of our GLP-1 research peptides hub.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered to activate two incretin receptors at once: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. This dual GIP/GLP-1 agonism distinguishes it from single agonists like semaglutide and from triple agonists like retatrutide. A fatty-acid (C20 diacid) chain is attached to the peptide to extend its duration of action.
Mechanism of action
In the published literature, simultaneous GIP and GLP-1 receptor activation is described as enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and modulating appetite through central nervous system signaling. The dual mechanism is frequently cited as the rationale for the magnitude of metabolic effects observed in trials of the drug product, relative to single GLP-1 agonism.
Half-life and pharmacokinetics
Tirzepatide is reported in the literature to have an elimination half-life of approximately five days (around 116 hours), which is the basis for once-weekly dosing of the pharmaceutical drug product. Its fatty-acid modification promotes binding to albumin, slowing clearance. These pharmacokinetic properties are characterized in published studies of the approved drug, not in the research-grade material supplied here.
What the clinical literature reports
Tirzepatide as a pharmaceutical drug product has been characterized across two large clinical trial programs conducted by its sponsor: SURPASS (type 2 diabetes) and SURMOUNT (weight management), with results published in journals including the New England Journal of Medicine. These trials studied the approved drug product in humans — not research-grade material — and are summarized here only to explain the science. Researchers should consult primary sources on PubMed.
Dosing used in the clinical trials
The following reports the dose regimens administered in published clinical trials of the tirzepatide drug product, for scientific context only. It is not a recommendation, a protocol, or guidance for use, and it does not describe how the research-grade material sold here should be used. Self-administering research peptides can be dangerous; these products are strictly for laboratory research.
In the SURMOUNT-1 obesity trial (Jastreboff et al., New England Journal of Medicine, 2022), tirzepatide was given once weekly by subcutaneous injection on a fixed escalation schedule — starting at 2.5 mg and increasing by 2.5 mg every 4 weeks toward assigned maintenance doses of 5, 10, or 15 mg. The gradual ramp is described in the literature as a way to improve gastrointestinal tolerability.
Tirzepatide weekly dose by titration step — SURMOUNT 1 (to 15 mg)
At the 15 mg maintenance dose, SURMOUNT 1 reported a mean body-weight reduction of about 20.9% over 72 weeks. The separate type 2 diabetes program (SURPASS) studied 5, 10, and 15 mg maintenance doses. Sources: SURMOUNT 1 (NEJM 2022); FDA prescribing information.
Laboratory handling
Research-grade tirzepatide ships as a lyophilized (freeze-dried) powder and is characterized by HPLC, with a Certificate of Analysis available on our Lab Results page. Before use it is reconstituted with sterile bacteriostatic water; our reconstitution calculator returns the exact diluent volume, and the reconstitution guide walks through the procedure. You can view research-grade tirzepatide in our catalog; bacteriostatic water is included free with every order. For a side-by-side with the single agonist, see Semaglutide vs Tirzepatide.
Frequently asked questions
Is tirzepatide a peptide?
Yes — tirzepatide is a synthetic 39-amino-acid peptide with a fatty-acid modification. It acts as a dual GIP/GLP-1 receptor agonist.
What is the half-life of tirzepatide?
Published studies report an elimination half-life of roughly five days (about 116 hours), which underlies once-weekly dosing of the drug product.
How is research-grade tirzepatide characterized?
By HPLC analysis with a third-party Certificate of Analysis documenting identity and purity, typically at ≥99%.
What diluent is used to reconstitute it?
Sterile bacteriostatic water is the standard diluent; the exact volume depends on the vial’s milligram content and the target concentration. Our reconstitution calculator returns the precise amount.
Disclaimer: Research-grade tirzepatide supplied by MyGLP1Store is strictly for laboratory and in-vitro research. It is not an approved drug, not a supplement, and not for human or veterinary use. Clinical trial data above pertains to the pharmaceutical drug product studied by its sponsor.